Aberdeen Group plc Lowers Stock Position in Medpace Holdings, Inc. $MEDP

Key Points

• Aberdeen Group plc reduced its stake in Medpace Holdings by 33.6% during the second quarter, owning 42,556 shares valued at approximately $13.36 million after selling 21,553 shares.
• Analysts have varied perspectives on Medpace, with recent ratings including a downgrade from Cowen to "sell" while Deutsche Bank lifted its price target from $270 to $430, sustaining a "hold" rating.
• Medpace reported a 14.2% year-over-year revenue growth to $603.31 million for the last quarter, exceeding analysts' expectations and posting earnings of $3.10 per share.

Aberdeen Group plc reduced its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 33.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,556 shares of the company's stock after selling 21,553 shares during the period. Aberdeen Group plc owned 0.15% of Medpace worth $13,357,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after buying an additional 37 shares in the last quarter. Brooklyn Investment Group lifted its position in shares of Medpace by 244.8% during the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after buying an additional 71 shares in the last quarter. Whittier Trust Co. lifted its position in shares of Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after buying an additional 35 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Medpace by 223.3% during the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company's stock valued at $61,000 after buying an additional 134 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Medpace during the 1st quarter valued at about $60,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MEDP has been the topic of a number of research analyst reports. Cowen cut Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft boosted their price target on Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a report on Wednesday, July 23rd. Weiss Ratings reissued a "buy (b-)" rating on shares of Medpace in a report on Wednesday, October 8th. Barclays boosted their price target on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Finally, Rothschild & Co Redburn cut Medpace from a "buy" rating to a "neutral" rating and boosted their price target for the stock from $342.00 to $474.00 in a report on Wednesday, September 3rd. Two investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Reduce" and a consensus price target of $424.10.

Medpace Price Performance

NASDAQ:MEDP opened at $514.32 on Thursday. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $547.15. The stock's 50 day simple moving average is $488.51 and its two-hundred day simple moving average is $378.75. The company has a market cap of $14.45 billion, a price-to-earnings ratio of 38.24, a PEG ratio of 3.24 and a beta of 1.40.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same quarter in the previous year, the company posted $2.75 EPS. The company's revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Activity

In other news, President Jesse J. Geiger sold 41,801 shares of the business's stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $453.11, for a total transaction of $18,940,451.11. Following the transaction, the president owned 36,503 shares of the company's stock, valued at approximately $16,539,874.33. The trade was a 53.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the business's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the transaction, the general counsel directly owned 10,343 shares in the company, valued at approximately $4,654,350. This represents a 22.48% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 161,266 shares of company stock worth $74,111,427. Company insiders own 20.30% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.